Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Accelerated Share Repurchases	Share Repurchase Program	Common Stock	Common Stock Accelerated Share Repurchases	Common Stock Share Repurchase Program	Additional Paid-in Capital	Additional Paid-in Capital Accelerated Share Repurchases	Additional Paid-in Capital Share Repurchase Program	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance at Dec. 31, 2022	$ 496,008			$ 29			$ 820,335			$ (86)	$ (324,270)
Beginning balance, common stock, outstanding (in shares) at Dec. 31, 2022				29,008,368
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised	$ 25,809			$ 1			25,808
Stock options exercised (in shares)	595,188			595,188
Vesting of restricted stock units, net (in shares)				40,915
Shares held for tax withholdings	$ (17,158)						(17,158)
Shares held for tax withholdings (in shares)				(113,062)
Issuance of common stock	353						353
Issuance and sale of common stock (in shares)				1,575
Issuance of common stock for employee stock purchase plan	5,299						5,299
Issuance of common stock for employee stock purchase plan (in shares)				27,480
Stock-based compensation expense	82,470						82,470
Other comprehensive (loss) income	886									886
Net (loss) income	(21,153)										(21,153)
Ending balance at Dec. 31, 2023	572,514			$ 30			917,107			800	(345,423)
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2023				29,560,464
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised	$ 21,897						21,897
Stock options exercised (in shares)	387,856			376,730
Vesting of restricted stock units, net	$ (4,895)						(4,895)
Vesting of restricted stock units, net (in shares)				57,824
Issuance of common stock	322						322
Issuance and sale of common stock (in shares)				1,716
Issuance of common stock for employee stock purchase plan	5,605						5,605
Issuance of common stock for employee stock purchase plan (in shares)				48,599
Stock-based compensation expense	116,007						116,007
Accelerated share repurchase of common stock		$ (75,000)						$ (75,000)
Accelerated share repurchase of common stock (in shares)					(305,157)
Other comprehensive (loss) income	(264)									(264)
Net (loss) income	53,509										53,509
Ending balance at Dec. 31, 2024	$ 689,695			$ 30			981,043			536	(291,914)
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2024	29,740,176			29,740,176
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised	$ 9,393			$ 0			9,393
Stock options exercised (in shares)	163,445			140,479
Vesting of restricted stock units, net	$ (22,840)						(22,840)
Vesting of restricted stock units, net (in shares)				266,525
Issuance of common stock	307						307
Issuance and sale of common stock (in shares)				2,580
Issuance of common stock for employee stock purchase plan	5,019						5,019
Issuance of common stock for employee stock purchase plan (in shares)				52,015
Stock-based compensation expense	130,259						130,259
Accelerated share repurchase of common stock			$ (176,023)			$ (1)			$ (176,022)
Accelerated share repurchase of common stock (in shares)					(103,886)	(1,518,874)
Other comprehensive (loss) income	(72)									(72)
Net (loss) income	145,422										145,422
Ending balance at Dec. 31, 2025	$ 781,160			$ 29			$ 927,159			$ 464	$ (146,492)
Ending balance, common stock, outstanding (in shares) at Dec. 31, 2025	28,579,015			28,579,015

Inspire Medical Systems, Inc. 10-K